Can-fite Biopharma LTD Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
AMEX
SCHEDULE 13G/A: Orca Capital AG Discloses 4.1% Stake in Can-Fite BioPharma Following Recent Offering
Orca Capital AG has filed an amended Schedule 13G, reporting a 4.1% beneficial ownership stake in Can-Fite BioPharma Ltd., calculated after the issuer's recent registered offering.
AMEX
Orca Capital AG has reported a 9.7% beneficial ownership stake in Can-Fite BioPharma Ltd., holding 375 million ordinary shares.
AMEX
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a beneficial ownership of 4.99% of Can-Fite BioPharma Ltd.'s common stock as of December 31, 2024.